Convexity Scientific, Inc.

Current customers and patients will continue with existing programs while integrated and enhanced solutions are expected in coming monthsNEW HAVEN, Conn., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wellinks, the industry leader in virtual-led cardiopulmonary care, announced today it has acquired Spire Health in a non-cash transaction. The acquisition merges Spire’s novel patient monitoring technology with Wellinks highly specialized virtual-led cardiopulmonary care model creating a first of its kind fully integrated Predictive Patient Care company. As part of the agreement, Wellinks welcomes to the board of directors Mr. Rich Wilmot who will represent Spire’s majority investor Gilde Healthcare. “By combining these companies, we are now at the forefront of applying predictive analytics to the clinical care of cardiopulmonary patients,” said Wellinks Chairman and Managing Partner of HighCape Capital, Kevin Rakin. “With this acquisition, Wellinks can now offer payors and providers a new means of managing COPD and CHF patients, utilizing patient data, predictive analytics, and highly specialized treatment pathways, all within our Predictive Patient Care model.” Rich Wilmot, Partner HealthTech Venture & Growth at Gilde Healthcare commented, “We are eager to see the potential of combining these two companies, their technologies and outstanding people. Since our initial investment in Spire Health, we’ve recognized the medical need and business potential to bring a more data-driven approach to managing highly complex patients with cardiopulmonary conditions. We believe this combined entity will realize this potential through a highly integrated patient care model and are delighted to be part of this exciting endeavor.” COPD and CHF impact 14.2 million and 6.5 million people respectively in the United States creating two of the greatest care and cost challenges in the U.S. healthcare system. Wellinks’ Predictive Patient Care utilizes advanced predictive analytics to equip providers with information and clinical interventions designed to identify potential exacerbations and costly complications from these conditions before they rise to the level of emergency care and/or hospitalization. With early intervention most patients will remain at home or seek treatment from their primary healthcare professional in a much more clinically effective and cost-efficient setting, ultimately improving care while significantly reducing the costs. This approach holds great potential for reducing costs and improving outcomes for payors and providers in both the Value-Based-Care and Fee-For-Service markets. “We are thrilled to welcome Spire professionals into our organization, while also adding their amazing technology into our care models,” said Stacie Bratcher, CEO of Wellinks. “By uniting these companies, we are creating something entirely novel — Predictive Patient Care. Wellinks will now be able to passively monitor cardiopulmonary patients while leveraging machine learning to predict potential complications, often before the patient experiences symptoms. These findings, combined with our proprietary clinical processes will then provide payors and providers suggested interventions based on validated treatment pathways. This highly integrated approach to monitoring and treating cardiopulmonary patients will be a first of its kind.” About COPD and CHF costsChronic Obstructive Pulmonary Disease (COPD) and Congestive Heart Failure (CHF) cost the U.S. healthcare system $24 billion and $49 billion, respectively, each year. The majority of these costs are driven by exacerbations that often result in emergency department (ED) visits and hospital admission. For example, 47% of COPD patients will experience one or more exacerbations annually, and of those who are hospitalized, 30% will readmit within 30 days and 64% will readmit within 12 months. Similarly, 50% of CHF costs are driven by ED visits and hospitalizations. Each hospital admission can cost as much as $14,000. About Predictive Patient CarePredictive Patient Care is a patient management approach that integrates patient data, AI-enabled analytics, predictive models and evidence-based care to identify complications and intervene at the right time with the right patient. About WellinksFounded in 2012 and headquartered in New Haven, CT, Wellinks has a rich history of innovation in cardiopulmonary care. From pioneering the development of a portable, connected nebulizer to now spearheading advancements in Predictive Patient Care, Wellinks remains at the forefront of healthcare innovation. Our cutting-edge data collection, analysis, and intervention model empowers clinicians to predict and prevent adverse events across a spectrum of cardiopulmonary conditions. By reducing complications, enhancing patient outcomes, and lowering healthcare costs, Wellinks is transforming the future of care delivery. For more information, visit www.wellinks.com and follow on LinkedIn. About Spire HealthSpire Health is the leading digital healthcare company for continuous respiratory monitoring and actionable feedback. The Spire Health Tag enables remote patient monitoring with unparalleled adherence and clinical-grade accuracy. Spire Health’s remote patient monitoring approach has the potential to identify and predict health events, enable early interventions, and prevent hospital admissions. For more information visit: spirehealth.com

NEW HAVEN, Conn., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Wellinks, is thrilled to announce its selection as a quarterfinalist for the prestigious 2024 Digital Health Hub Foundation: Digital Health Awards. Wellinks was chosen as a quarterfinalist for the Rising Star - Home Health Diagnostic award. This recognition highlights the company's dedication to innovation and excellence in pulmonary health. The Digital Health Awards celebrate organizations that demonstrate excellence in leveraging digital advancements to enhance healthcare services and patient outcomes. As a quarterfinalist, Wellinks stands out for its commitment to enhancing virtual care for those with chronic respiratory disease, so they achieve healthier lives. This recognition highlights Wellinks for its significant contributions to advancing the management of chronic pulmonary disease and empowering people to live fully and breathe freely. The Digital Health Hub Foundation Awards honor organizations making strides in improving healthcare speed, efficiency and equity with their digital innovations. Being named a quarterfinalist reflects Wellinks commitment to driving meaningful change in the healthcare landscape. “Here at Wellinks we’re breaking the access issues to bring virtual care into the home so we can provide interventions and change the course of disease for these patients,” said Dr. Abi Sunddaramoorthy, Chief Medical Officer at Wellinks. Out of a substantial pool of over 1,500 submissions, only the most promising 16 quarterfinalists per category, per track have advanced to this stage. "This year has set a new benchmark for excellence, with a remarkable influx of global submissions showcasing groundbreaking innovations in digital health. The level of ingenuity and commitment we’ve seen is truly inspiring. Congratulations to all our quarterfinalists for their outstanding achievements," said Mark Goldstein, Chairman of the Digital Health Hub Foundation. Finalists will be announced September 22, 2023, and the winners will be announced at the Grand Finale taking place at HLTH on October 21, 2024. About Digital Health Hub Foundation: Our mission is to help the world’s next best innovative healthcare companies scale and grow. Founded in 2017, on the campus of UCSF in San Francisco, our now 30,000 member community consists of thousands of early-to late-stage healthcare companies and highly qualified healthcare industry providers, payors, experts, mentors, investors, clinicians and researchers who participate in our annual awards ceremony where we bring together the industry to honor and validate the best of the best and celebrate the technological advances in healthcare and the impact it has. About Wellinks Wellinks is on a mission to help those with chronic obstructive pulmonary disease (COPD) live fully and breathe freely. COPD is the third leading cause of death by chronic disease in the U.S. and the fifth most costly chronic disease. With its personalized, virtual-first COPD management system, Wellinks breaks down barriers for patients, providing the evidence-based care they need and deserve outside the four walls of the clinic. Wellinks supports patients through virtual pulmonary rehabilitation, health coaching, and monitoring through connected devices and an easy-to-use smartphone app. Based in New Haven, Connecticut, Wellinks is led by a team of digital health veterans and backed by top investment firms including Morningside, HighCape Capital, Connecticut Innovations, and Benslie. For more information, visit www.wellinks.com and follow on Twitter (@WellinksHealth) and LinkedIn.Press Contact:Amy Johnstonamy.johnston@wellinks.com

Learnings from ongoing Healthy at Home Study at UMass Chan Medical School pave the way for expansion of innovative COPD care at homeNEW HAVEN, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Wellinks, a digital healthcare company offering comprehensive value-based solutions for Chronic Obstructive Pulmonary Disease (COPD) management, today announced plans to integrate its pulmonary rehabilitation program at UMass Memorial Health (UMMH) to support people living with Chronic Obstructive Pulmonary Disease (COPD) in Central Massachusetts. In collaboration with UMMH’s Center for Digital Health Solutions (CDHS) and the UMMH Digital Health Clinic (DHC), Wellinks will provide physicians and care teams with additional tools to support virtual pulmonary rehabilitation, dedicated care management, remote monitoring, and specialized nursing care. Wellinks’ COPD disease management program will be available for UMMH patients who have been discharged from the hospital following a COPD exacerbation, as well as those receiving outpatient care from their pulmonologists and/or primary care providers. Wellinks will help ensure care teams receive regular updates on patient progress and can coordinate proactive care when needed. “There is tremendous opportunity to improve access to pulmonary rehabilitation in the United States,” said Stacie Bratcher, Chief Executive Officer at Wellinks. “Since 2022, Wellinks and UMass Chan Medical School have collaborated to demonstrate our program’s value in the Healthy at Home study. We are excited to work with UMass Memorial Health and expand access to our services for more individuals living with COPD in the Central Massachusetts community.” COPD is the third leading cause of death by chronic disease in the United States and the fifth most costly chronic disease, with one-in-five people patients readmitted within 30 days of discharge. The Centers for Disease Control and Prevention estimates a total of $49.9 billion is spent annually on COPD treatment, driven largely by frequent emergency department visits and hospitalizations caused by exacerbations. Despite evidential findings that pulmonary rehabilitation is both cost effective and improves COPD health outcomes, a shortage of centers nationwide limits access for many patients. To expand access, the American Thoracic Society updated clinical practice guidelines in 2023 to recommend telerehabilitation and remote or virtual monitoring for patients with COPD and other chronic respiratory diseases. “UMass Memorial Health and UMass Chan are committed to empowering patients and removing barriers to care in all areas, including preventative care, which is critical to improving clinical outcomes and overall quality of life for patients,” said John Broach, MD, MPH, associate professor of emergency medicine and director of the Division of Disaster Medicine in the Department of Emergency Medicine. “This collaboration will help simplify the care journeys of people living with COPD in our region.” In 2022, UMass Chan Medical School’s Program in Digital Medicine and Wellinks recognized the need to improve the management of COPD at home and conducted a study to assess the feasibility of app-based consumer technology and comprehensive virtual disease management to improve quality of life and achieve better health outcomes among people with COPD. This ongoing study inspired the integration of Wellinks’ pulmonary rehabilitation program across the UMMH system. “Finding new ways for patients to receive high quality care from the comfort of their own homes was a key driver for our Healthy at Home study,” said principal investigator Apurv Soni, MD, PhD’21, assistant professor of medicine and co-director of the Program in Digital Medicine. “Our work with Wellinks is critical for improving patient outcomes, making care more efficient, and closing health equity gaps for patients with COPD.” About UMass Memorial HealthUMass Memorial Health is the largest not-for-profit health care system in Central Massachusetts with 17,000 employees and 2,100 physicians. Our comprehensive system includes UMass Memorial Medical Center, UMass Memorial Health – Harrington, UMass Memorial Health – HealthAlliance-Clinton Hospital, UMass Memorial Health – Marlborough Hospital, UMass Memorial Health – Community Healthlink, and UMass Memorial Medical Group. We are the clinical partner of UMass Chan Medical School. For more information, visit www.ummhealth.org. About WellinksWellinks is on a mission to help those with chronic obstructive pulmonary disease (COPD) live fully and breathe freely. COPD is the third leading cause of death by chronic disease in the U.S. and the fifth most costly chronic disease. With its personalized, virtual-first COPD management system, Wellinks breaks down barriers for patients, providing the evidence-based care they need and deserve outside the four walls of the clinic. Wellinks supports patients through virtual pulmonary rehabilitation, health coaching, and monitoring through connected devices and an easy-to-use smartphone app. Based in New Haven, Connecticut, Wellinks is led by a team of digital health veterans and backed by top investment firms including Morningside, HighCape Capital, Connecticut Innovations, and Benslie. For more information, visit www.wellinks.com and follow on Twitter (@WellinksHealth) and LinkedIn. About UMass Chan Medical SchoolUMass Chan Medical School, one of five campuses of the University of Massachusetts system, comprises the T.H. Chan School of Medicine, the Morningside Graduate School of Biomedical Sciences, the Tan Chingfen Graduate School of Nursing, ForHealth Consulting of UMass Chan Medical School and MassBiologics. At UMass Chan, we are advancing together to improve the health and wellness of our diverse communities throughout Massachusetts and across the world by leading and innovating in education, research, health care delivery and public service. UMass Chan is perennially ranked in the top 10 percent of medical schools for primary care education and among the top 50 medical schools in the nation for biomedical research funding. Learn more at www.umassmed.edu. Press Contact: Abby CohenAbigail.cohen@wellinks.com